<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00423514</url>
  </required_header>
  <id_info>
    <org_study_id>06-125</org_study_id>
    <secondary_id>MSKCC-06125</secondary_id>
    <nct_id>NCT00423514</nct_id>
  </id_info>
  <brief_title>Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease</brief_title>
  <official_title>A Phase I/II Dose Escalation Trial of Clofarabine, in Addition to Melphalan and Thiotepa as Myeloablative Regimen Followed by an Allogeneic Unmodified Hematopoietic Stem Cell Transplant From HLA-Compatible Related or Unrelated Donors for the Treatment of High Risk and/or Advanced Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy, such as clofarabine, melphalan, and thiotepa, before a donor&#xD;
      stem cell transplant helps stop the growth of cancer or abnormal cells. It also helps stop&#xD;
      the patient's immune system from rejecting the donor's stem cells. When the healthy stem&#xD;
      cells from a donor are infused into the patient they may help the patient's bone marrow make&#xD;
      stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted&#xD;
      cells from a donor can also make an immune response against the body's normal cells. Giving&#xD;
      tacrolimus and mycophenolate mofetil before the transplant may stop this from happening.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of clofarabine when&#xD;
      given together with melphalan and thiotepa, followed by a donor stem cell transplant and to&#xD;
      see how well it works in treating patients with high-risk and/or advanced hematologic cancer&#xD;
      or other disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of clofarabine when administered with melphalan and&#xD;
           thiotepa followed by allogeneic stem cell transplantation in patients with high-risk&#xD;
           and/or advanced hematologic malignancies. (Phase I)&#xD;
&#xD;
        -  Determine the 1-year disease-free survival of patients treated with this regimen. (Phase&#xD;
           II)&#xD;
&#xD;
        -  Determine the efficacy of this regimen, in terms of antileukemic potential and relapse&#xD;
           rate, in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Evaluate the incidence and severity of nonhematologic toxicity of this regimen in these&#xD;
           patients.&#xD;
&#xD;
        -  Evaluate the incidence and severity of graft-versus-host disease in patients treated&#xD;
           with this regimen.&#xD;
&#xD;
      OUTLINE: This is a phase I, dose-escalation study of clofarabine followed by an open-label,&#xD;
      phase II study. Patients are stratified according to HLA-compatible donor type (related vs&#xD;
      unrelated).&#xD;
&#xD;
        -  Cytoreductive therapy: Patients receive clofarabine IV over 2 hours once daily on days&#xD;
           -9 to -5, thiotepa IV over 4 hours on day -4, and melphalan IV over 30 minutes once&#xD;
           daily on days -3 and -2.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of clofarabine until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
        -  Graft-versus-host disease (GVHD) prophylaxis: Patients who undergo bone marrow or&#xD;
           peripheral blood stem cell transplantation receive tacrolimus IV continuously over 24&#xD;
           hours or orally every 8-12 hours beginning on day -3 and methotrexate IV on days 1, 3,&#xD;
           6, and 11. Patients who undergo UCB transplantation receive tacrolimus IV continuously&#xD;
           over 24 hours or orally every 8-12 hours beginning on day -3 and mycophenolate mofetil&#xD;
           (MMF) IV or orally 2 or 3 times daily on days -3 to 45 followed by a taper until day 100&#xD;
           (unless there are signs of acute GVHD). Patients who undergo UCB transplantation without&#xD;
           GVHD continue tacrolimus for 6 months followed by a taper and discontinued 1 year after&#xD;
           transplantation.&#xD;
&#xD;
        -  Allogeneic hematopoietic stem cell transplantation (HSCT) or allogeneic umbilical cord&#xD;
           blood (UCB) transplantation: Patients undergo allogeneic HSCT (bone marrow or peripheral&#xD;
           blood stem cells) or double UCB transplantation on day 0. Patients also receive&#xD;
           filgrastim (G-CSF) IV or subcutaneously beginning on day 7 and continuing until blood&#xD;
           counts recover.&#xD;
&#xD;
        -  Maintenance therapy: Approximately 2 months after transplantation patients with ALL, M4&#xD;
           or M5 AML, and those transplanted with AML in bone marrow relapse receive cytarabine&#xD;
           intrathecally (IT) monthly for up to 5 doses. Patients with a history of CNS leukemia&#xD;
           receive cytarabine IT once monthly during months 2-12 after HSCT.&#xD;
&#xD;
      After completion of study therapy, patients are followed periodically for at least 4 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 42 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 20, 2006</start_date>
  <completion_date type="Actual">June 18, 2021</completion_date>
  <primary_completion_date type="Actual">June 18, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse of leukemia</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall and disease-free survival</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early post-transplant regimen-related severe morbidity (grade III to IV nonhematologic toxicity) and mortality as measured by the NCI Cancer Therapy Evaluation Program CTCAE v 3.0</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Graft Versus Host Disease</condition>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>cytoreduction regimen &amp; stem cell transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a single arm phase I/II clinical trial to assess efficacy (the antileukemic potential and relapse rate), and safety (peri-transplant morbidity and mortality) of a novel cytoreduction regimen in preparation for allogeneic hematopoietic stem cell transplantation (HSCT).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <arm_group_label>cytoreduction regimen &amp; stem cell transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clofarabine</intervention_name>
    <arm_group_label>cytoreduction regimen &amp; stem cell transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <arm_group_label>cytoreduction regimen &amp; stem cell transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <arm_group_label>cytoreduction regimen &amp; stem cell transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <arm_group_label>cytoreduction regimen &amp; stem cell transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thiotepa</intervention_name>
    <arm_group_label>cytoreduction regimen &amp; stem cell transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
    <arm_group_label>cytoreduction regimen &amp; stem cell transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
    <arm_group_label>cytoreduction regimen &amp; stem cell transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <arm_group_label>cytoreduction regimen &amp; stem cell transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of 1 of the following:&#xD;
&#xD;
               -  Acute myelogenous leukemia, meeting 1 of the following criteria:&#xD;
&#xD;
                    -  In first complete remission (CR), meeting 1 of the following criteria:&#xD;
&#xD;
                         -  Poor risk [no t(15,17), inv 16, or t(8,21)]&#xD;
&#xD;
                         -  Not a candidate for total body irradiation (TBI)&#xD;
&#xD;
                         -  Any infant in first CR&#xD;
&#xD;
                    -  In second CR, meeting the following criteria:&#xD;
&#xD;
                         -  All patients&#xD;
&#xD;
                    -  In more than second CR OR relapsed/refractory disease, meeting the following&#xD;
                       criteria:&#xD;
&#xD;
                         -  All patients&#xD;
&#xD;
                         -  Blast percentage &gt; 5% and &lt; 25% in bone marrow (BM) at the time of stem&#xD;
                            cell transplantation (SCT)&#xD;
&#xD;
               -  Acute lymphoblastic leukemia, meeting 1 of the following criteria:&#xD;
&#xD;
                    -  In first CR, meeting 1 of the following criteria:&#xD;
&#xD;
                         -  Poor risk [t(9;22), t(4;11) AND no CR after 7-28 days of induction]&#xD;
&#xD;
                         -  Not a candidate for TBI&#xD;
&#xD;
                         -  Any infant in first CR&#xD;
&#xD;
                    -  In second CR, meeting the following criteria:&#xD;
&#xD;
                         -  All patients&#xD;
&#xD;
                    -  In more than second CR OR relapsed/refractory disease, meeting the following&#xD;
                       criteria:&#xD;
&#xD;
                         -  All patients&#xD;
&#xD;
                         -  Blast percentage &gt; 5% and &lt; 25% in BM at the time of SCT&#xD;
&#xD;
                    -  Acute undifferentiated or biphenotypic leukemia, meeting the following&#xD;
                       criteria:&#xD;
&#xD;
                         -  All patients&#xD;
&#xD;
                         -  Blast percentage &gt; 5% and &lt; 25% in BM at the time of SCT&#xD;
&#xD;
                    -  Chronic myelogenous leukemia, meeting the following criteria:&#xD;
&#xD;
                         -  All patients&#xD;
&#xD;
                         -  In first chronic phase&#xD;
&#xD;
                    -  Myelodysplastic syndrome, meeting 1 of the following criteria:&#xD;
&#xD;
                         -  Primary high risk disease&#xD;
&#xD;
                              -  Stage &gt; RAEB1&#xD;
&#xD;
                         -  Secondary high risk disease&#xD;
&#xD;
                              -  All patients&#xD;
&#xD;
                              -  Any stage&#xD;
&#xD;
                         -  Juvenile myelomonocytic leukemia&#xD;
&#xD;
                              -  All patients&#xD;
&#xD;
          -  No doubling of peripheral blast counts within a period of 2 weeks&#xD;
&#xD;
          -  No active CNS disease&#xD;
&#xD;
          -  HLA-compatible donor available meeting 1 of the following criteria:&#xD;
&#xD;
               -  Related donor&#xD;
&#xD;
                    -  Genotypically or phenotypically matched at ≥ 7 or 8 of HLA-A, -B, -C and&#xD;
                       -DRB1 alleles&#xD;
&#xD;
               -  Unrelated donor meeting 1 of the following criteria:&#xD;
&#xD;
                    -  8 of 8 alleles matched&#xD;
&#xD;
                    -  For patients &lt; 18 years old only: 7 or 8 alleles matched with the mismatch&#xD;
                       at only 1 HLA-A, -B, -C, or -DRB1 allele&#xD;
&#xD;
          -  Two HLA-compatible unrelated cord blood (UCB) units available meeting the following&#xD;
             criteria:&#xD;
&#xD;
               -  HLA-matched minimally at 4 of 6 HLA-A, HLA-B, and DRB1 allele&#xD;
&#xD;
                    -  HLA-A and HLA-B matched at intermediate resolution by molecular technique&#xD;
&#xD;
                    -  DRB1 allele matched at high resolution by molecular technique&#xD;
&#xD;
               -  Both matched UCB units with cryopreserved nucleated cell dose ≥ 1.5 x 10^7/kg&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky OR Lansky performance status 70-100%&#xD;
&#xD;
          -  SGOT &lt; 2 times upper limit of normal&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 mg/dL (unless there is liver disease involvement)&#xD;
&#xD;
          -  Creatinine normal OR creatinine clearance &gt; 60 mL/min&#xD;
&#xD;
          -  LVEF &gt; 50% at rest OR shortening fraction ≥ 29%&#xD;
&#xD;
          -  Patients with asymptomatic pulmonary disease with no prior risk factors OR symptomatic&#xD;
             pulmonary disease with diffusion capacity &gt; 50% of predicted (corrected for&#xD;
             hemoglobin) are eligible&#xD;
&#xD;
          -  No active uncontrolled viral, bacterial, or fungal infection&#xD;
&#xD;
          -  No known HIV I or II positivity&#xD;
&#xD;
          -  No known human T-cell lymphotrophic virus I or II positivity&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No hydroxyurea within the past 2 weeks&#xD;
&#xD;
          -  No allogeneic or autologous stem cell transplantation within the past 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>54 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Farid Boulad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 16, 2007</study_first_submitted>
  <study_first_submitted_qc>January 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2007</study_first_posted>
  <last_update_submitted>June 21, 2021</last_update_submitted>
  <last_update_submitted_qc>June 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>graft versus host disease</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>acute undifferentiated leukemia</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>juvenile myelomonocytic leukemia</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Clofarabine</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

